BPC-157 as an Investigational Peptide Therapeutic: Biopharmaceutical Challenges, Formulation Strategies, and Translational Development Barriers.
This peer-reviewed analysis critically examines BPC-157’s development barriers as a pharmaceutical candidate, identifying significant unresolved challenges: no approved formulation exists, dosing regimens lack validation, and no Phase II trials have been completed despite 30+ years of preclinical research. The paper systematically addresses biopharmaceutical obstacles including physicochemical properties, pharmacokinetic-pharmacodynamic disconnects, formulation hurdles across administration routes, and regulatory/translational barriers. For practitioners and supplement brands, this represents authoritative documentation of why BPC-157 remains investigational and the specific scientific gaps between preclinical promise and clinical reality.